Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
dose proportionality
Description:
Dose proportionality describes how drug exposure, such as concentration or area under the curve, changes in relation to the administered dose in pharmacokinetic studies.
Related topics:
Pharmacogenetics and Drug Metabolism (11%),
Antibiotics Pharmacokinetics and Efficacy (8%)
OpenAlex ID:
keywords/dose-proportionality
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
2007
·
Joachim Stangier
, Karin Rathgen
, et al.
·
British Journal of Clinical Pharmacology
·
892
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects
2005
·
Dagmar Kubitza
, Michael Becka
, et al.
·
European Journal of Clinical Pharmacology
·
640
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
2013
·
Kevin Fitzgerald
, Maria Frank-Kamenetsky
, et al.
·
The Lancet
·
589
Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual‐Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi)
2009
·
Jessie Gu
, Adele Noe
, et al.
·
The Journal of Clinical Pharmacology
·
527
The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
2002
·
H. Agersø
, L. B. Jensen
, et al.
·
Diabetologia
·
512
PDF
Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers
2000
·
Craig W. Hendrix
, Charles Flexner
, et al.
·
Antimicrobial Agents and Chemotherapy
·
512
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects
2018
·
Lesley Taylor
, Barry Gidal
, et al.
·
CNS Drugs
·
507
PDF
The Clinical Pharmacokinetics of Levofloxacin
1997
·
Douglas N. Fish
, Andrew T. Chow
·
Clinical Pharmacokinetics
·
490
Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I Trial With Chronic Myeloid Leukemia Patients
2004
·
Bin Peng
, Michael Hayes
, et al.
·
Journal of Clinical Oncology
·
481
PDF
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
2006
·
Marja K. Pasanen
, Mikko Neuvonen
, et al.
·
Pharmacogenetics and Genomics
·
478
Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers
2010
·
Koichiro Ogata
, Jeanne Mendell‐Harary
, et al.
·
The Journal of Clinical Pharmacology
·
458
Similar Elimination Rates of Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients and Healthy Subjects
2003
·
T. Vilsbøll
, H. Agersø
, et al.
·
The Journal of Clinical Endocrinology & Metabolism
·
451
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus
2005
·
Orville G. Kolterman
, Dennis D. Kim
, et al.
·
American Journal of Health-System Pharmacy
·
440
Safety, Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects
2002
·
Cynthia A. Guzzo
, Christine I. Furtek
, et al.
·
The Journal of Clinical Pharmacology
·
436
Pharmacokinetics and Tissue Penetration of Fluconazole in Humans
1990
·
K. W. Brammer
, P. R. Farrow
, et al.
·
Clinical Infectious Diseases
·
436
Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802
1999
·
George He
, Joseph Massarella
, et al.
·
Clinical Pharmacokinetics
·
418
Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens
2002
·
L. Purkins
, N. Wood
, et al.
·
Antimicrobial Agents and Chemotherapy
·
415
Clinical Pharmacokinetics of Diclofenac: Therapeutic Insights and Pitfalls
1997
·
Neal M. Davies
, Keith E. Anderson
·
Clinical Pharmacokinetics
·
415
Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.
2001
·
Fergus McTaggart
, Linda Buckett
, et al.
·
The American Journal of Cardiology
·
413
Effects of Dosing Condition on the Oral Bioavailability of Green Tea Catechins after Single-Dose Administration of Polyphenon E in Healthy Individuals
2005
·
H-H. Sherry Chow
, Iman A. Hakim
, et al.
·
Clinical Cancer Research
·
409
The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers
2002
·
Gary H Kamimori
, Chetan S Karyekar
, et al.
·
International Journal of Pharmaceutics
·
408
Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2
2021
·
Wendy P. Painter
, Wayne Holman
, et al.
·
Antimicrobial Agents and Chemotherapy
·
406
Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Bone Metastases
2002
·
Tianling Chen
, James Berenson
, et al.
·
The Journal of Clinical Pharmacology
·
376
Apixaban, an oral, direct factor X a inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
2012
·
Charles Frost
, Jessie Wang
, et al.
·
British Journal of Clinical Pharmacology
·
375
PDF
Confidence Interval Criteria for Assessment of Dose Proportionality
2000
·
Brian P. Smith
, Francois R. Vandenhende
, et al.
·
Pharmaceutical Research
·
362
Show more works
View as search
Works count:
5,513
Citation count:
147,200
Year
Topic
Type